Advertisement

Topics

Antibody developer Visterra to be purchased by Otsuka

05:50 EDT 12 Jul 2018 | SmartBrief

Antibody developer Visterra will be acquired by Otsuka Pharmaceutical for $430 million cash, giving the buyer programs based  -More

Original Article: Antibody developer Visterra to be purchased by Otsuka

NEXT ARTICLE

More From BioPortfolio on "Antibody developer Visterra to be purchased by Otsuka"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...